Haemonetics Corp (HAE) 20 Days SMA touches -11.59%: The odds favor the bear

Haemonetics Corp (NYSE: HAE) kicked off on Tuesday, up 1.48% from the previous trading day, before settling in for the closing price of $60.64. Over the past 52 weeks, HAE has traded in a range of $58.80-$97.97.

During the last 5-year period, the sales growth of Healthcare Sector giant was 6.80%. While this was happening, its average annual earnings per share was recorded 14.78%. With a float of $49.44 million, this company’s outstanding shares have now reached $50.24 million.

Let’s determine the extent of company efficiency that accounts for 3657 employees. In terms of profitability, gross margin is 52.38%, operating margin of 15.02%, and the pretax margin is 11.99%.

Haemonetics Corp (HAE) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Haemonetics Corp is 1.59%, while institutional ownership is 112.74%. The most recent insider transaction that took place on Nov 11 ’24, was worth 565,692. Before that another transaction happened on Jul 26 ’24, when Company’s President, Global Hospital sold 4,312 for $91.15, making the entire transaction worth $393,039. This insider now owns 18,196 shares in total.

Haemonetics Corp (HAE) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.1 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 14.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.30% during the next five years compared to 17.09% growth over the previous five years of trading.

Haemonetics Corp (NYSE: HAE) Trading Performance Indicators

Take a look at Haemonetics Corp’s (HAE) current performance indicators. Last quarter, stock had a quick ratio of 2.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.25. Likewise, its price to free cash flow for the trailing twelve months is 32.23.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.54, a number that is poised to hit 1.22 in the next quarter and is forecasted to reach 5.01 in one year’s time.

Technical Analysis of Haemonetics Corp (HAE)

Looking closely at Haemonetics Corp (NYSE: HAE), its last 5-days average volume was 2.37 million, which is a jump from its year-to-date volume of 1.02 million. As of the previous 9 days, the stock’s Stochastic %D was 12.66%. Additionally, its Average True Range was 3.38.

During the past 100 days, Haemonetics Corp’s (HAE) raw stochastic average was set at 7.57%, which indicates a significant decrease from 18.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.64% in the past 14 days, which was higher than the 41.70% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $76.19, while its 200-day Moving Average is $81.34. However, in the short run, Haemonetics Corp’s stock first resistance to watch stands at $62.70. Second resistance stands at $63.86. The third major resistance level sits at $65.44. If the price goes on to break the first support level at $59.96, it is likely to go to the next support level at $58.38. Should the price break the second support level, the third support level stands at $57.22.

Haemonetics Corp (NYSE: HAE) Key Stats

The company with the Market Capitalisation of 3.09 billion has total of 50,237K Shares Outstanding. Its annual sales at the moment are 1,309 M in contrast with the sum of 117,560 K annual income. Company’s last quarter sales were recorded 348,540 K and last quarter income was 37,490 K.